Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhanced Autologous PSMA-CAR T in Refractory Castration Resistant Prostate Cancer
NCT06228404Phase 1Active, not recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Mar 2024
- Primary completion
- Aug 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enhanced autologous PSMA-CAR T in castration-resistant prostate cancer (CRPC), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events at 6 months and 1 more. Started Mar 2024; status: active, not recruiting.
02
Drugs
enhanced autologous PSMA-CAR T
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT06228404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06228404.